Waldencast plc Announces Intention to Voluntarily Delist from Nasdaq and Deregister its Securities under the Exchange Act

Waldencast will voluntarily delist its Class A shares and warrants from Nasdaq, with the last expected trading day on October 2, 2026, and plans to suspend SEC reporting after filing Form 15 around October 5. Following the Obagi Medical divestiture, the company is a single-brand Milk Makeup business and will seek shareholder approval to rename itself Milk Makeup plc and pursue OTC quotation under ticker MLKM. The board expects to eliminate a substantial portion of $18.5 million in 2025 central-headquarters costs, but shareholders face materially reduced liquidity, research coverage and public disclosure.

Analysis

WALD faces a predictable forced-seller and liquidity-discount cycle into the final Nasdaq trading date: index-ineligible holders, mandates requiring SEC reporting, and retail brokers that restrict OTC custody can all become sellers irrespective of operating performance. The claimed overhead reduction is economically meaningful only if it converts into sustained brand investment or free cash flow; without continuing disclosures, minority investors have little ability to verify whether savings are retained, reinvested, or absorbed by stand-alone costs. The unresolved disposition of sale proceeds is the key near-term value driver, not the corporate-name change.

Over the next 1-3 months, the scheduled trading update is the last broadly accessible operating datapoint before reporting opacity increases. A weak update or an ambiguous capital-allocation decision should widen the discount sharply because there is no obvious public-market catalyst after deregistration; conversely, a disclosed cash distribution, tender, or credible audited pro forma balance sheet could support a short-covering rally before the liquidity event. The structural 6-18 month outcome is binary: a focused prestige-cosmetics asset may earn higher returns without public-company friction, but OTC status materially raises governance, valuation, and eventual-exit discounts.

ULTA has little direct earnings sensitivity, but retains modest optionality as an important prestige-beauty distribution channel if Milk redirects cost savings into retail marketing and product velocity. The contrarian case is that the apparent negative signal is primarily a microcap market-structure event rather than evidence of deteriorating demand; however, that does not make WALD investable for a liquid institutional book absent a defined liquidity mechanism or independently verifiable balance-sheet value.

Key Decisions for Investors

• Avoid initiating or adding to WALD for long-only liquid portfolios before the final Nasdaq session; OTC execution, custody and information risk dominate any fundamental upside over the next 2-6 weeks.
• For event-driven accounts able to hold restricted-liquidity securities, monitor the upcoming trading update and proceeds-allocation decision rather than buy the delisting dip. Consider a small long only if disclosed net cash plus a quantified distribution/tender establishes downside support; exit if no capital-return framework is announced before the Form 15 filing.
• Do not short WALD as a primary expression: borrow availability and forced-cover risk around the last listed trading day can make downside economics unattractive. A short is only actionable if borrow is confirmed through settlement and the stock rallies materially on unsupported cost-savings claims.
• Maintain ULTA as neutral; reassess only if subsequent channel data show Milk-driven category velocity or promotional intensity affecting prestige-cosmetics gross margin. The likely impact is immaterial versus ULTA's broader assortment and does not justify a standalone trade.